Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Mersana Therapeutics's accounts receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Mersana Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 0.00.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Mersana Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.17.
Mersana Therapeutics Accounts Receivable Historical Data
The historical data trend for Mersana Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Mersana Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Mersana Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Mersana Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Mersana Therapeutics Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Mersana Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Mersana Therapeutics (Mersana Therapeutics) Business Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRSN has been successfully added to your 